Premarket Testing and Validation - PowerPoint PPT Presentation

1 / 10
About This Presentation
Title:

Premarket Testing and Validation

Description:

Phase 1, 20 100, adverse effects, dose size ... Phase 3, 100's 1000s, safety, dose, effectiveness ~ 1/5000. FDA New Drug Approval ... – PowerPoint PPT presentation

Number of Views:16
Avg rating:3.0/5.0
Slides: 11
Provided by: paulh8
Category:

less

Transcript and Presenter's Notes

Title: Premarket Testing and Validation


1
Premarket Testing and Validation
  • "The greatest lesson in life is to know
  • that even fools are right sometimes"
  • Sir Winston Churchill

2
Standard Tests
  • Cycle testing on/off, etc.
  • Typical use testing Elec. Mech. Test,
    typical, aim for MTBF values
  • 10 x 10 testing 10 samples, 10 tests, goal is
    repeatability variability value

3
10 x 10 test
unit 1 2 10 mean S.D.
1 repeat-
2 ability

10
mean varia bility gt
S.D.
4
Software Testing
  • Designers should specify test information sheets
    to check validity
  • Prioritized by safety, reliability, performance,
    other
  • Testing by components, then final

5
Validation and Verification Test Method
Commonality
  • Check hardware software
  • Implement a common test set
  • Use data generator tools (canned batch mode data
    files, etc.)

6
Verification Validation Reporting
  • Time/ of cycles run
  • Tasks performed
  • Summary of task results
  • Summary of errors resolution
  • Description location
  • Impact
  • Assessment of the software reliability

7
Essentials of software testing
  • Quality of tests gt success
  • Use early life-cycle testing
  • Test now, not later
  • Require one to be responsible
  • Use trained, disciplined personnel for testing
  • Test creatively, use teamwork

8
Drug Development
  • gt 2 billion prescriptions/year of FDA regulated
    drugs
  • same non-prescription (may be post control)
    drugs
  • gt 400,000,000 developmental costs per new drug
  • Test new compounds
  • Computer models, test
  • Test compounds from nature

9
Drug testing
  • 2 animal models, based upon parallels to human
    sensitivity to disease studied
  • Rodents
  • Rabbits
  • Dogs, cats
  • Primates

10
Clinical Trials Considerations
  • FDA
  • IRB
  • Phase 1, 20 100, adverse effects, dose size
  • Phase 2, several 100, short term safety,
    effectiveness
  • Phase 3, 100s 1000s, safety, dose,
    effectiveness
  • 1/5000
  • FDA New Drug Approval
  • Phase 4, long term followup studies
Write a Comment
User Comments (0)
About PowerShow.com